# Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain

> **NIH NIH K23** · YALE UNIVERSITY · 2021 · $191,700

## Abstract

PROJECT SUMMARY/ABSTRACT
 This proposal seeks to investigate the analgesic and anti-craving efficacy of Cannabidiol (CBD) for
comorbid opioid use disorder (OUD) and chronic pain. Chronic pain afflicts approximately 70% of people with
OUD. Opioid agonist treatment effectively reduces opioid use overdose deaths, but does not alleviate chronic
pain. Convergent preclinical studies have shown that cannabinoids reduce pain sensitivity and opioid-seeking
behavior, suggesting they could be leveraged for treatment. Yet, the therapeutic efficacy of cannabinoids for
comorbid OUD and chronic pain remains unknown. Given CBD’s lack of hedonic properties and established
analgesic and anti-craving effects, it holds particular therapeutic promise for this population.
 Quantitative Sensory Testing (QST) is a computerized pain assessment method used to reliably
measure antinociception and predict the pain treatment response. QST pain biomarkers can be integrated with
behavioral paradigms to investigate the two-pronged efficacy of CBD for alleviating pain sensitivity and cue-
induced opioid craving. The objective of this proposal is to apply behavioral pharmacology, multimodal pain
research and clinical trial methods to study the safety and therapeutic efficacy of CBD for people with comorbid
OUD and chronic pain. This will have a significant impact for this patient population, by (i) determining the
safety of acute CBD administration (Aim 1); (ii) determining the dose of CBD required to reduce pain sensitivity
and cue-induced opioid craving (Aim 2); (iii) understanding the safety of long-term CBD co-administration with
opioid agonist maintenance (Aim 3), and (iv) providing preliminary data on the efficacy of CBD to reduce pain
severity/interference and opioid craving in the clinical setting (Aim 4). Aims 1 and 2 will be carried out through
human laboratory study, and Aims 3 and 4 will be executed through a pilot clinical trial. These studies will
serve as the basis for novel treatments and therapeutic biomarkers for comorbid OUD and chronic pain.
 This proposal will integrate state-of-the-art facilities at Yale and at the VA Connecticut, with established
collaborations with local opioid treatment programs. The applicant has assembled a renowned team of expert
mentors in the fields of opioid, cannabinoid and pain research. This proposal builds on preliminary work on
cannabinoid modulation of pain sensitivity in humans with comorbid OUD and chronic pain. Formal didactics,
symposia and national scientific meetings will support the applicant’s training. Specific training goals include
developing exceptional skills in (i) behavioral pharmacology of addiction (ii) multimodal assessment of pain, (iii)
clinical trials and advanced biostatistics, (iv) grant writing, and (v) responsible conduct of research. Finally, this
application leverages the applicant’s robust clinical foundation as a board-certified addiction psychiatrist. The
vital support from this K23 award will all...

## Key facts

- **NIH application ID:** 10105046
- **Project number:** 1K23DA052682-01
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Joao Paulo De Aquino
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $191,700
- **Award type:** 1
- **Project period:** 2021-05-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10105046

## Citation

> US National Institutes of Health, RePORTER application 10105046, Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain (1K23DA052682-01). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10105046. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*